Princeton, New Jersey, Oct. 24 (Bloomberg Data) -- Amgen Inc. (AMGN US) was raised to ``outperform'' from ``neutral'' by analyst Michael Aberman at Credit Suisse. The 12-month price target is $65.00 per share.